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Article abstrac+We evaluated the frequency of depression and psychosis 
in 46 patients with AD and 135 control subjects with the apolipoprotein 
(APO) E3/3 or E3l4 genotype. Patients with AD and the APOE3/4 genotype 
had a more than threefold increase in the signs of depression and psychosis 
when compared with either patients with the APOE313 genotype or to control 
subjects. Our preliminary study suggests that  the phenotype of AD associated 
with the €4 allele is more likely to include psychiatric manifestations. 
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The €4 isoform of the apolipoprotein (apo) E gene is 
associated with AD.’ Evaluation of the clinical phe- 
notypes of AD with isoforms of the APOE gene may 
offer insight into possible roles of the apoE4 protein 
in AD. Lopez-Alberola et a1.2 found no differences in 
the psychiatric, demographic, neurologic, or neuro- 
imaging features of 31 AD patients with the 
APOE4I- genotype and 31 AD patients with other 
APOE genotypes. However, the study was small, 
control subjects were not included, and the frequency 
of other alleles was unspecified. 
We hypothesized that patients with AD and the €4 
allele would be phenotypically different from patients 
with AD without the €4 allele and from control sub- 
jects. We focused on the presence or absence of psychi- 
atric manifestations because the frequency of depres- 
sion and psychosis is high in patients with AD3-5 and 
disturbances in neuronal circuitry and neurotransmit- 
ter imbalances are common to both AD and psychiatric 
illnesses and therefore proteins such as apoE may in- 
fluence psychiatric manifestations in AD. 
Methods. Data were available from a previously de- 
scribed, community based, longitudinal study of the el- 
derly, representative of individuals over 65 residing in the 
area.6 All subjects had a neuropsychological battery, a 17- 
item Hamilton Depression Rating Scale (HDRS), and a 
screen for psychosis adapted from the Screening Clinical 
Interview with the DSM-111-R (SCID). A diagnosis of prob- 
able AD was made using the National Institute of Neu- 
rological and Communicative Disorders and Stroke- 
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Alzheimer’s Disease Related Disorders Association cri te- 
ria. The severity of cognitive impairment was assessed by 
the clinical dementia rating scale (CDR), the total recall 
score on the Bushke selective reminding memory test, and 
the Blessed cognitive sc0re.~.7 
Patients were excluded from the study if they had geno- 
types other than APOE313 or APOE314, because these ge- 
notypes were less frequent or if they had possible AD (im- 
plying a potential additional cause for their dementia). We 
included patients with AD and a CDR between 0.5 (very 
mild ADIR and 2 (moderate AD). Subjects were divided into 
four categories based on the APOE3/3 or APOE314 geno- 
type and the presence or absence of AD. 
For depression, we evaluated the total HDRS score. For 
psychosis, we used questions dealing with delusions and 
hallucinations from the adapted SCID pooled for an  overall 
psychosis score with 1 point for each affirmative answer 
(maximum score of 3). Scores were evaluated both as con- 
tinuous and categorical variables. For the categorical vari- 
ables, we used a cutoff score of 10 or more for the HDRS 
(60% sensitivity and 88% specificity for the diagnosis of 
major depression in patients with ADI9 and psychosis was 
rated as present or absent. 
Demographic variables were analyzed using the Stu- 
dent’s t-test or x 2  analysis and Fisher’s exact tests. With 
control subjects of the APOE313 genotype as reference, the 
scores as continuous outcome variables were analyzed us- 
ing analysis of variance, with and without adjusting for 
age, education and severity of dementia (using CDR, total 
recall, or Blessed score). The presence or absence of the 
dichotomized categorical outcome variables of HDRS and 
psychosis scores were analyzed using x 2  analysis, Fisher’s 
Table 1 Demographic characteristics 
Subjects by diagnosis Subjects by genotype 
Variable Control subjects (CI) Patients (AD) P APOE3/3 APOE3J4 P 
Number of subjects 
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exact tests, and logistic regression analysis both before and 
after adjusting for age, education, and seventy of demen- 
tia. The analysis was repeated among patients using 
APOE3/3 patients as reference. 
Results. Of 181 eligible subjects, 46 had AD (APOE3/3 
[26] ;  APOE3/4 [20]) and 135 were control subjects 
(APOE3/3 [981; APOE3/4 [371) (table 1) .  We evaluated eth- 
nicity because the association between APOE4 and AD 
may differ among races.' There was no difference in the 
outcome variables of psychosis and HDRS scores among 
the different ethnic groups. Patients with AD and the 
APOE3/4 genotype show higher HDRS and psychosis 
scores when compared with APOE3/3 control subjects 
when scores were analyzed both as continuous (table 2) 
and as categorical (table 3) variables. The difference re- 
mained significant after adjusting for age, education, and 
severity of dementia and was not seen when APOE3/4 
control subjects or APOE3/3 patients were compared with 
APOE3f3 control subjects. When compared with patients 
with the APOE3/3 genotype, patients with the APOE3/4 
genotype show higher HDRS and psychosis scores when 
the scores were analyzed as continuous variables, and 
these results approached significance when the scores 
were analyzed as categorical variables (see tables 2 and 3). 
Discussion. Our results suggest that patients 
with AD and the APOE314 genotype may have more 
psychiatric impairment than their peers with the 
APOE313 genotype or control subjects of either geno- 
type. The at  least threefold increase in psychiatric 
symptomatology does not appear to  be due to differ- 
ences in age, education, or severity of dementia as it 
persisted after adjusting for them. 
APOE4 increases risk of AD either by altering the 
properties of p-amyloid or tangle formation,l and this 
may predispose patients with the €4 allele to in- 
creased frequency of psychiatric symptoms. Patients 
with AD and psychosis have an overall trend toward 
increased numbers of senile plaques (SPs) and tan- 
gles throughout the brain with more SPs in the pre- 
subiculum and increased neurofibrillary tangles in 
the middle frontal cortex as compared with AD pa- 
tients without psych~sis.~ Patients with AD and de- 
pression show accelerated degeneration of the locus 
ceruleus and substantia nigra.4 Autopsies on pa- 
tients with AD and the €4 allelelo reveal overall in- 
creased numbers of plaques and tangles when com- 
pared with patients with AD and the APOE313 
genotype, with significant increases in SPs in the 
middle frontal, superior temporal, and inferior pari- 
etal areas and the CA1 area of the hippocampus that 
is near the presubiculum, although the substantia 
nigra and locus ceruleus were not examined.1° The 
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Table 2 HDRS and psychosis scores as continuous variables for all subjects using APOE313-CZ subjects as reference and for patients 
only using APOE313-AD patients as reference 
~~ ~~ 
Mean 
Score t p value adjusted p value adjusted p value adjusted 
standard for age, for age, for age, 
deviation education and education and education and 
Symptom Group (sd) P CDR total recall score Blessed score 








HDRS score D O E 3  1 3 - m  
APOE314-AD 
Psychosis score APOE3 13-AD 
APOE3/4-AD 
4.83 5 4.78 
5.46 2 4.12 
5.62 2 3.90 
8.70 f 6.30 
0.36 t 0.66 
0.35 t 0.56 
0.57 t 0.90 
0.90 f 0.85 
5.46 ? 4.12 
8.70 +. 6.30 
0.35 t 0.56 

















































similarities in the neuropathologic profiles of pa- 
tients with AD and the €4 allele and patients with 
AD and psychopathology may help explain the in- 
creased frequency of psychiatric symptoms among 
patients with AD and the €4 allele. 
Neurochemically, patients with AD and psychosis 
have more noradrenaline in the substantia nigra and 
less serotonin in the subicular region of the brain.3 
Patients with AD and depression have reduced nor- 
adrenaline in the neocortex and trends toward reduced 
levels in all brain areas for both serotonin and nor- 
adrenaline.5 The neurochemical pattern of patients 
with AD and the APOE isoforms has not been studied. 
Patients with the €4 allele have an earlier onset of 
AD.' We did not examine disease duration. Thus, the 
increased frequency of psychiatric symptoms may be 
explained by a longer duration of AD among our 
APOE3f4 patients. However, this explanation is un- 
likely as symptoms such as depression and psychosis 
are poorly correlated with AD d ~ r a t i o n . ~ - ~  Also, by 
adjusting for age and severity of dementia, we effec- 
tively adjusted for differences in ages of onset of AD 
among genotypes. Hence, our results cannot be ex- 
plained simply by differences in ages of onset or of 
duration of AD between groups. Alternatively, if we 
postulate the psychiatric symptoms to be influenced 
by SP deposition, SP deposition in AD is not corre- 
lated with illness durati0n.l 
Table 3 HDRS and psychosis scores as categorical variables for all subjects using APOE313-CZ subjects as reference and for patients 
only using APOE313-AD patients as reference 
Symptom Group 
~ -. ~ 
HDRS APOE313-CI 




score 2 1  1 APOE313-AD 
APOE314-CI 
APOE3/4-AD 
HDRS APOE 313-AD 
21 10 APOE314-AD 
Psychosis APOE313-AD 
score 2 1 APOE3/4-AD 
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Further evaluation of the clinical, neuropatho- 
logic, and neurochemical differences in AD with dif- 
ferent isoforms of APOE may provide valuable infor- 
mation as to  the role of the €4 allele in the 
pathogenesis of AD. 
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